Center for Thyroid Cancer, National Cancer Center, Goyang, Republic of Korea.
Department of Surgery, Seoul National University Bundang Hospital and College of Medicine, Seongnam, Republic of Korea.
Thyroid. 2022 Jul;32(7):772-780. doi: 10.1089/thy.2021.0619.
Active surveillance (AS) is offered as a choice to patients with low-risk papillary thyroid microcarcinoma (PTMC). This study aimed to identify patient and physician factors associated with the choice of AS. We conducted a cross-sectional survey of patients with low-risk PTMC who were enrolled in a prospective study comparing outcomes following AS and surgery. Patients completed a questionnaire to assess their prior knowledge of the disease, considerations in the decision-making process, and reasons for choosing the treatment. We also surveyed 19 physician investigators about their disease management preferences. Variables affecting the patients' choice of AS, including patients' characteristics and their decision-making process, were analyzed in a multivariable analysis. The response rate of the patient survey was 72.8% (857/1177). Among the patients who responded to the survey, 554 patients (128 male; mean age 49.4 ± 11.6 years; response rate 73.4%) with low-risk PTMC chose AS (AS group), whereas 303 patients (55 male; 46.6 ± 10.7 years; 71.8%) chose immediate surgery (iOP group). In the AS group, 424 patients (76.5%) used a decision aid, and 144 (47.5%) used it in the iOP group. The choice of AS was associated with the following variables: patient age >50 years (odds ratio 1.713 [confidence interval, CI 1.090-2.690], = 0.020), primary tumor size ≤5 mm (odds ratio 1.960 [CI 1.137-3.379], = 0.015), and consulting an endocrinologist (odds ratio 114.960 [CI 48.756-271.057], < 0.001), and use of a decision aid (odds ratio 2.469 [CI 1.320-4.616], = 0.005). The proportion of patients who were aware of AS before their initial consultation for treatment decision was higher in the AS group than in the iOP group (64.6% vs. 56.8%). Family members were reported to have influenced the treatment decisions more in the iOP group ( = 0.025), whereas the AS group was more influenced by information from the media ( = 0.017). Physicians' attitudes regarding AS of low-risk PTMC tended to be more favorable among endocrinologists than surgeons and all became more favorable as the study progressed. Emerging evidence suggests that physicians' attitudes and communication tools influence the treatment decision of low-risk PTMC patients. Support is needed for patient-centered decision making. (Clinical trial No: NCT02938702).
主动监测(AS)被作为低危甲状腺微小乳头状癌(PTMC)患者的一种选择。本研究旨在确定与 AS 选择相关的患者和医生因素。
我们对参加比较 AS 和手术治疗后结局的前瞻性研究的低危 PTMC 患者进行了横断面调查。患者完成了一份问卷,以评估他们对疾病的先前了解、决策过程中的考虑因素以及选择治疗方法的原因。我们还调查了 19 名医师调查员对疾病管理的偏好。在多变量分析中,分析了影响患者 AS 选择的变量,包括患者特征和决策过程。
患者调查的回复率为 72.8%(1177 名患者中有 857 名)。在接受调查的患者中,554 名患者(男性 128 名;平均年龄 49.4±11.6 岁;回复率 73.4%)患有低危 PTMC,选择了 AS(AS 组),而 303 名患者(男性 55 名;46.6±10.7 岁;71.8%)选择了立即手术(iOP 组)。在 AS 组中,424 名患者(76.5%)使用了决策辅助工具,而 144 名患者(47.5%)在 iOP 组中使用了该工具。AS 的选择与以下变量相关:患者年龄>50 岁(优势比 1.713[置信区间,CI 1.090-2.690],=0.020)、原发肿瘤大小≤5 mm(优势比 1.960[CI 1.137-3.379],=0.015)、咨询内分泌学家(优势比 114.960[CI 48.756-271.057],<0.001)和使用决策辅助工具(优势比 2.469[CI 1.320-4.616],=0.005)。在 AS 组中,在最初接受治疗决策咨询之前,有更多的患者了解 AS(64.6%比 56.8%)。在 iOP 组中,家庭成员对治疗决策的影响更大(=0.025),而 AS 组更多地受到媒体信息的影响(=0.017)。随着研究的进展,内分泌学家对低危 PTMC 的 AS 态度往往比外科医生更有利,所有医生的态度都变得更加有利。
新出现的证据表明,医生的态度和沟通工具会影响低危 PTMC 患者的治疗决策。需要支持以实现以患者为中心的决策。(临床试验注册号:NCT02938702)。